Page 9 - Genentech News Today

The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and 10

Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) and Curis (NASDAQ:CRIS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends. Analyst Ratings This is a summary of current […]

Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) and Curis (NASDAQ:CRIS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends. Profitability This table compares Scinai Immunotherapeutics and Curis’ […]

Cardiovascular disease in chronic obstructive pulmonary disease (COPD) is common and the leading cause of death among patients with mild to moderate

This randomized trial assesses whether acetaminophen would increase the number of days alive and free of organ support to day 28 among critically ill

Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.

MIT biology student Hanjun Lee had planned to pursue chemistry at MIT. A course in genetics changed that, noting, “There’s a beauty in studying and finding the patterns in nature.”

Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% At week 24, 100% of CT-388...

Investegate announcements from OBD and King's College London collaborate on RA

Operator: Good morning, ladies and gentlemen, and welcome to the Adaptimmune Q1 2024 Financial and Business Update Conference Call. I would now like to turn the meeting over to Ms. Juli Miller.